<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872885</url>
  </required_header>
  <id_info>
    <org_study_id>425965</org_study_id>
    <secondary_id>KF5503/37</secondary_id>
    <nct_id>NCT00872885</nct_id>
  </id_info>
  <brief_title>Bunionectomy Trial With GRT6005</brief_title>
  <official_title>A Randomized, Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Moderate to Severe Pain Following Bunionectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tris Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tris Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine whether the new centrally acting analgesic is&#xD;
      effective in comparison to placebo and an active comparator (morphine).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of pain intensity 2-10 hours after Investigational medicinal product intake. Pain assessments</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of rescue medication</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse Events reported by the participant as well as electrocardiogram, a measure of electrical activity of the heart and laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue medication</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>liquid formulation, 200 to 600 µg, single dose, one day</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Morphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>60 mg</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dosage</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects scheduled to undergo primary unilateral first metatarsal bunionectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl,&#xD;
             hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound&#xD;
             planned to be used during the anesthesia, or their excipients.&#xD;
&#xD;
          -  Concomitant inflammatory disease.&#xD;
&#xD;
          -  Life-long history of seizure disorder or epilepsy.&#xD;
&#xD;
          -  Subjects with impaired renal function&#xD;
&#xD;
          -  Subjects with impaired hepatic function&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Resting pulse rate is &lt;50bpm or &gt;100 bpm after 5 minutes rest in supine position&#xD;
&#xD;
          -  resting blood pressure after 5 minutes rest in supine position: Systolic blood&#xD;
             pressure is &lt;100mmHg or &gt;140 mmHg Diastolic blood pressure is &lt;60 mmHg or &gt; 90 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Bothmer, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Grünenthal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Research Group Ltd</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <disposition_first_submitted>June 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>June 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 14, 2010</disposition_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>analgesic</keyword>
  <keyword>bunionectomy</keyword>
  <keyword>surgery</keyword>
  <keyword>post operative pain</keyword>
  <keyword>single Hallux valgus repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

